Impact of discontinuing fluoroquinolone prophylaxis on early mortality after allogeneic marrow or peripheral blood SCT with myeloablative conditioning.

摘要

Oral fluoroquinolones (FQs) or other antibiotics are commonly used as antibacterial prophylaxis after cytotoxic chemotherapy for malignant neoplasms, although significant practice variations have been reported among centers and countries. Despite such practical variations, the efficacy of oral FQ as a prophylactic agent has not been fully evaluated in the SCT setting. Further, the widespread emergence of multidrug-resistant microorganisms in hematology-oncology units has also increased the need for re-evaluating the role of antibacterial prophylaxis administered to patients undergoing cytotoxic chemotherapy or SCT.